YM BioSciences' partner, Oncoscience AG, commences patient treatment in phase III trial in Germany with nimotuzumab MISSISSAUGA, ON, April 27...
Update - YM BioSciences to acquire Eximias Pharmaceutical Corporation - U.S. based Eximias to become a wholly-owned subsidiary of YM...
YM BioSciences to acquire Eximias Pharmaceutical Corporation - U.S. based Eximias to become a wholly-owned subsidiary of YM - MISSISSAUGA, ON...
YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germanywith nimotuzumab - Phase II results presented at the 27th Annual...
YM BioSciences initiates Non-Small-Cell Lung Cancer trial with nimotuzumab - First patient treated in Canada with trial to expand to Korea...
YM BioSciences closes US $ 40 million financing MISSISSAUGA, ON, Feb. 17 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer...
YM BioSciences raises US $ 40 million MISSISSAUGA, Canada, Feb. 14 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product...
YM BioSciences receives FDA fast track designation for tesmilifene in advanced breast cancer MISSISSAUGA, Canada, Feb. 13 /CNW/ - YM BioSciences...
YM BioSciences reports second quarter 2006 operational and financial results MISSISSAUGA, ON, Feb. 10 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
YM Biosciences' subsidiary DELEX Therapeutics announces enrollment of first patient in Phase IIb trial for the treatment of acute pain with...
YM Biosciences expands development and commercialization program for EGFr inhibitor nimotuzumab MISSISSAUGA, ON, Nov. 17 /CNW/ - YM BioSciences...
YM Biosciences reports first quarter 2006 operational and financial results MISSISSAUGA, ON, Nov. 14 /CNW/ - YM BioSciences Inc. (AMEX:YMI...
Positive Phase II prostate cancer results with YM BioSciences' lead cancer drug tesmilifene published in Journal of Urology MISSISSAUGA, ON, Oct...
YM BioSciences completes enrolment of pivotal trial for tesmilifene - First interim analysis planned for mid-2006 could lead to approval...
YM BioSciences partner, Oncoscience AG, reports update of pediatric brain cancer data - Nimotuzumab (Theraloc; TheraCIM h-R3) Phase II results...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.